ISSN: 2218-6751

Journal Home

Journal Guideline

Translational Lung Cancer Research Q1 Unclaimed

AME Publishing Company Hong Kong

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Translational Lung Cancer Research is a journal indexed in SJR in Oncology with an H index of 70. It has an SJR impact factor of 1,243 and it has a best quartile of Q1. It has an SJR impact factor of 1,243.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Oncology (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

1,243

SJR Impact factor

70

H Index

324

Total Docs (Last Year)

835

Total Docs (3 years)

12307

Total Refs

2768

Total Cites (3 years)

725

Citable Docs (3 years)

2.72

Cites/Doc (2 years)

37.98

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Molecular Cancer Q1
JAMA oncology Q1
Journal of Thoracic Oncology Q1
Cancer Discovery Q1
Neuro-Oncology Q1

Compare this journals

Aims and Scope

Best articles by citations

Improving outcomes for brain metastases in EGFR mutated NSCLC

Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next

Spread through air spaces in lung neuroendocrine tumor

Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more

New first-line treatment strategies for advanced lung squamous cell carcinoma

Screening of potential biomarkers and their predictive value in early stage non-small cell lung cancer: a bioinformatics analysis

Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock

CT-based radiomics signature for the stratification of N2 disease risk in clinical stage I lung adenocarcinoma

Flexible bronchoscopy-guided microwave ablation in peripheral porcine lung: a new minimally-invasive ablation

Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?

SHOW MORE ARTICLES

Surveillance of ground glass nodules - when is enough, enough?

Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors

Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer

Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer

Awareness: potential toxicities of carbon nanotubes

Robot-assisted thoracoscopic surgery versus thoracotomy for c-N2 stage NSCLC: short-term outcomes of a randomized trial

Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)? - the shifting paradigm of therapeutics

Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19

Optimal management of pulmonary ground-glass opacity nodules

Cyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer

Application of the CARE guideline as reporting standard in the Translational Lung Cancer Research

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer